These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 1431312)
1. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta. Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312 [TBL] [Abstract][Full Text] [Related]
2. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously. Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767 [TBL] [Abstract][Full Text] [Related]
4. Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle. Schiller JH; Horisberger MA; Bittner G; Carlin JM; Storer B; Byrne GI; Willson JK; Borden EC J Biol Response Mod; 1990 Aug; 9(4):368-77. PubMed ID: 2395002 [TBL] [Abstract][Full Text] [Related]
5. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759 [TBL] [Abstract][Full Text] [Related]
7. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488 [TBL] [Abstract][Full Text] [Related]
8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion. Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942 [TBL] [Abstract][Full Text] [Related]
9. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects. Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332 [TBL] [Abstract][Full Text] [Related]
11. Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. Witt PL; Spear GT; Helgeson DO; Lindstrom MJ; Smalley RV; Borden EC J Interferon Res; 1990 Aug; 10(4):393-402. PubMed ID: 2121851 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618 [TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia. Liberati AM; Horisberger MA; Garofani P; De Angelis V; Ferrajoli A; Di Clemente F; Caricchi P; Adiuto D; Fedeli L; Palumbo B J Interferon Res; 1994 Dec; 14(6):349-55. PubMed ID: 7897254 [TBL] [Abstract][Full Text] [Related]
14. Biochemical host response to interferon-beta. Liberati AM; Fizzotti M; Proietti MG; Di Marzio R; Schippa M; Biscottini B; Senatore M; Berruto P; Canali S; Peretti G J Interferon Res; 1988 Dec; 8(6):765-77. PubMed ID: 3068316 [TBL] [Abstract][Full Text] [Related]
15. Differential induction of 2',5'-oligoadenylate synthetase by IFN-beta ser and IFN-alpha 2 in serum-supplemented and serum-free HL-60 leukemic cell cultures. Fraioli M; Wu JM J Biol Regul Homeost Agents; 1989; 3(3):112-7. PubMed ID: 2624146 [TBL] [Abstract][Full Text] [Related]
17. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects. Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330 [TBL] [Abstract][Full Text] [Related]
19. Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men. Barouki FM; Witter FR; Griffin DE; Nadler PI; Woods A; Wood DL; Lietman PS J Interferon Res; 1987 Feb; 7(1):29-39. PubMed ID: 3035034 [TBL] [Abstract][Full Text] [Related]
20. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases]. Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]